Technology
Alterity Therapeutics to commercialise technology that breaks antibiotic resistance – Small Caps
The University of Queensland’s commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology…
The University of Queenslands commercial vehicle UniQuest has granted a licence allowing Alterity Therapeutics (ASX: ATH) to use its zinc ionophore technology in combating superbugs.
UniQuest has given Alterity exclusive worldwide rights to use its zinc ionophore technology in developing and commercialising therapies that re-sensitise bacteria to antibiotics.
Once Alterity has begun receiving commercial revenue from commercialising the technology, it will make milestone and royalty payments to UniQuest…
-
General20 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
General18 hours agoEveryday AI use brings a hidden climate cost
-
Noosa News23 hours agoBoat crash in Helensvale on the Gold Coast leaves man with life-threatening burns and another one injured
-
Noosa News22 hours agoBrisbane bands unite to help bassist’s cancer fight